Hepatocellular carcinoma: Clinical study of long-term survival and choice of treatment modalities

作     者：Ke-Tong Wu Cun-Chuan Wang Li-Gong Lu Wei-Dong Zhang Fu-Jun Zhang Feng Shi Chuan-Xing Li 

作者机构：Department of Medical Imaging and Interventional Radiology Cancer Center and State Key Laboratory of Oncology in South China Sun Yat-sen University the Center of Minimally Invasive SurgeryFirst Affiliated Hospital of Jinan University Cancer Center Guangdong General Hospital 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2013年第19卷第23期

页      面：3649-3657页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by Guangdong Province Natural Science Fund No.10451008901006151 

主　　题：Hepatocellular carcinoma Surgery Radiofrequency ablation Transcatheter arterial chemoembolization Statistical analysis Clinical study 

摘      要：AIM: To analyze the prognostic factors of 5-year survival and 10-year survival in hepatocellular carcinoma (HCC) patients, and to explore the reasons for longterm survival and provide choice of treatment modalities for HCC patients. METHODS: From January 1990 to October 2012, 8450 HCC patients were included in a prospective database compiled by the Information Center after hospital admission. Long-term surviving patients were included in a 10-year survival group (520 patients) and a 5-year survival group (1516 patients) for analysis. The long-term survival of HCC patients was defined as the survival of 5 years or longer. Clinical and biologic variables were assessed using univariate and multivariate analyses. The survival of patients was evaluated by follow-up data. RESULTS: The long-term survival of HCC patients was associated with the number of lesions, liver cirrhosis and Child-Pugh classification. It was not found to be associated with tumor diameter, histological stage, and pretreatment level of serum α-fetoprotein. The differences in clinical factors between the 5-year survival and the 10-year survival were found to be the number of lesions, liver cirrhosis, Child-Pugh classification, and time elapsed until first recurrence or metastasis. The survival period of different treatment modalities in the patients who survived for 5 years and 10 years showed significant differences: (in order of significance) surgery alone surgery-transcatheter arterial chemoembolization (TACE) TACE-radiofrequency ablation (RFA) TACE alone surgery-TACE-RFA. The 10-year survival of HCC patients was not associated with the choice of treatment ***: This retrospective study elucidated survival outcomes, prognostic factors affecting survival and treatment modalities in HCC patients.